AD
adalimumab (Humira / Raheara / Trudexa)
AbbVie, Inc. · TNF · Monoclonal Antibodies
Status
✓ Approved
Indications
20 conditions
Clinical Trials
519 total
Active Trials
101 ongoing
Targets
TNF
What is adalimumab?
Last updated: February 2025adalimumab is a monoclonal antibodies developed by AbbVie, Inc.. It is approved for therapeutic indications via injectable (others) or intraocular injection or intravenous (iv) or subcutaneous injection.
Drug Profile
| Generic Name | adalimumab |
| Brand Names | Humira, Raheara, Trudexa |
| Company | AbbVie, Inc. |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | TNF |
| Route | Injectable (Others), Intraocular Injection, Intravenous (IV), Subcutaneous Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, AbbVie, Inc.
Mechanism of Action
Molecular Targets
adalimumab acts on 1 molecular target:
| TNF | tumor necrosis factor (TNFA, TNF-alpha) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 519 clinical trials registered, with 101 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT07398651 | NA | Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients | ● Not Yet Recruiting |
| NCT06440629 | Phase 4 | A Multi-center, Open, Randomized, 18-month, Parallel-group, Superiority Study to Compare the Effect | ● Recruiting |
| NCT06941376 | Phase 2 | Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for P | ● Recruiting |
| NCT05305066 | NA | Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Ca | ● Recruiting |
| NCT03153319 | Phase 1 | Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Muco | ● Active Not Recruiting |
| NCT03412747 | Phase 3 | A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment P | Completed |
+515 more trials available with free account
Sign up free to view all clinical trials →Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
adalimumab is developed for 20 unique indications across 7 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Musculoskeletal and connective tissue disorders | Ankylosing spondylitis | ✓ Approved |
| Skin and subcutaneous tissue disorders | Psoriasis | ✓ Approved |
| Vascular disorders | Behcet's syndrome | ✓ Approved |
| Gastrointestinal disorders | Colitis ulcerative | ✓ Approved |
| Gastrointestinal disorders | Crohn's disease | ✓ Approved |
+15 more indications available with free account
Sign up free to view all indications →